Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting.

The article discusses the challenges of cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) and explores the potential of PI3K inhibitors in overcoming this resistance. The study found that PI3K inhibitors can effectively bypass Nrf2-mediated cisplatin resistance in HNSCC by inducing metabolic changes and re-sensitizing resistant cells to cisplatin. The research highlights the therapeutic potential of PI3K inhibitors, specifically gedatolisib, in combination therapies to address primary chemo-radiation failure in HNSCC. [Extracted from the article]